Identification of a stable immunosuppressive molecular subtype in esophageal squamous cell carcinoma based on inflammation-related genes

Abstract

Inflammation affects the progression and therapeutic response of esophageal squamous cell carcinoma (ESCC). The molecular subtypes based on inflammatory response are still under exploitation for clinical application. Expression of inflammation-related hallmark genes was extracted from three ESCC datasets for subtype clustering using the non-negative matrix factorization method. The most stable subtype across datasets was identified using a SubMap analysis. The immune status and molecular characteristics of the stable subtype were explored by comparing with other subtypes, and a classifier was constructed and evaluated using machine learning methods. We identified a subtype of ESCC with a higher inflammatory response score, supported by three datasets, indicating its prevalence. This subtype exhibited a high level of immune infiltration, enriched with CD8+ T cells and various immunosuppressive cells, along with elevated expression of immune checkpoints. It also showed a significant similarity to melanomas responsive to immune checkpoint inhibitor nivolumab, suggesting potential therapeutic benefits. Further analysis revealed that some hub genes in immune pathways likely contribute to the immunosuppressive microenvironment of the subtype and hold prognostic value. We developed an 11-gene classifier for this subtype with an impressive area under the curve (AUC) of 0.9871. Applying it to external data, we identified a group with a similar immunosuppressive environment and potential response to immune checkpoint inhibitors. Generally speaking, the stable subtype we identified will be helpful to guide clinical diagnosis and treatment for ESCC.

Keywords

esophageal squamous cell carcinoma / gene classifier / inflammation-related genes / molecular subtypes / tumor microenvironment

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.

[2] Sohda M, Kuwano H. Current status and future prospects for esophageal cancer treatment. Ann Thorac Cardiovasc Surg. 2017; 23(1): 1-11.

[3] Huang J, Koulaouzidis A, Marlicz W, et al. Global burden, risk factors, and trends of esophageal cancer: an analysis of cancer registries from 48 countries. Cancer. 2021; 13(1): 141.

[4] Wilke H, Muro K, van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15(11): 1224-1235.

[5] Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell. 2022; 40(3): 277-288.e3.

[6] Chen N, Xu X, Fan Y. Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going? Ther Adv Med Oncol. 2023; 15: 15.

[7] Zhang X, Peng L, Luo Y, et al. Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis. Nat Commun. 2021; 12(1): 5291.

[8] Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020; 12(1): 8.

[9] Liu W, Xie L, He YH, et al. Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting. Nat Commun. 2021; 12(1): 4961.

[10] Wang D, Dai J, Suo C, Wang S, Zhang Y, Chen X. Molecular subtyping of esophageal squamous cell carcinoma by large-scale transcriptional profiling: characterization, therapeutic targets, and prognostic value. Front Genet. 2022; 13: 1033214.

[11] Liu Z, Zhao Y, Kong P, et al. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. Cancer Cell. 2023; 41(1): 181-195.e9.

[12] Liu M, An H, Zhang Y, et al. Molecular analysis of Chinese oesophageal squamous cell carcinoma identifies novel subtypes associated with distinct clinical outcomes. EBioMedicine. 2020; 57: 57.

[13] The Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017; 541(7636): 169-175.

[14] Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420(6917): 860-867.

[15] Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021; 6(1): 263.

[16] Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015; 12(10): 584-596.

[17] Souza RF, Huo X, Mittal V, et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology. 2009; 137(5): 1776-1784.

[18] Saenz JB, Mills JC. Acid and the basis for cellular plasticity and reprogramming in gastric repair and cancer. Nat Rev Gastroenterol Hepatol. 2018; 15(5): 257-273.

[19] Baba Y, Nomoto D, Okadome K, et al. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 2020; 111(9): 3132-3141.

[20] Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019; 51(1): 27-41.

[21] Petitprez F, Meylan M, de Reyniès A, Sautès-Fridman C, Fridman WH. The tumor microenvironment in the response to immune checkpoint blockade therapies. Front Immunol. 2020; 11: 784.

[22] Xu X, Jing J. Inflammation-related parameter serve as prognostic biomarker in esophageal squamous cell carcinoma. Front Oncol. 2022; 12: 900305.

[23] Zhang X, Gari A, Li M, et al. Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti-PD-1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma. J Transl Med. 2022; 20(1): 61.

[24] Lin W, Gao J, Zhang H, et al. Identification of molecular subtypes based on inflammatory response in lower-grade glioma. Inflamm Regen. 2022; 42(1): 29.

[25] Brunet JP, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A. 2004; 101(12): 4164-4169.

[26] Lin DC. Large-scale genomic analyses reveal alterations and mechanisms underlying clonal evolution and immune evasion in esophageal cancer. Nat Commun. 2023; 14(1): 893.

[27] Li Y, Lu Z, Che Y, et al. Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma. Onco Targets Ther. 2017; 6(11): e1356147.

[28] Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018; 1711: 243-259.

[29] Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression -implications for anticancer therapy. Nat Rev Clin Oncol. 2019; 16(6): 356-371.

[30] Wang S, Wang J, Chen Z, et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol. 2024; 8(1): 31.

[31] Elieh Ali Komi D, Grauwet K. Role of mast cells in regulation of T cell responses in experimental and clinical settings. Clin Rev Allergy Immunol. 2018; 54(3): 432-445.

[32] Yin J, Yuan J, Li Y, et al. Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial. Nat Med. 2023; 29(8): 2068-2078.

[33] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4): 252-264.

[34] Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017; 171(4): 934-949 e16.

[35] Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020; 20(11): 662-680.

[36] Li M, Zhao J, Li X, et al. HiFreSP: a novel high-frequency sub-pathway mining approach to identify robust prognostic gene signatures. Brief Bioinform. 2020; 21(4): 1411-1424.

[37] Yang H, Su H, Hu N, et al. Integrated analysis of genome-wide miRNAs and targeted gene expression in esophageal squamous cell carcinoma (ESCC) and relation to prognosis. BMC Cancer. 2020; 20(1): 388.

[38] You B-H, Yoon JH, Kang H, Lee EK, Lee SK, Nam JW. HERES, a lncRNA that regulates canonical and noncanonical Wnt signaling pathways via interaction with EZH2. Proc Natl Acad Sci. 2019; 116(49): 24620-24629.

RIGHTS & PERMISSIONS

2024 The Author(s). Precision Medical Sciences published by John Wiley & Sons Australia, Ltd on behalf of Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital.